Liposarcoma
Liposarcoma is the most common malignant soft tissue tumor in adults, accounting for 15–20% of all soft tissue sarcomas. It arises when undifferentiated mesenchymal precursor cells develop into abnormal fat-forming cells (lipoblasts). Unlike a benign lipoma, liposarcoma can invade locally, destroy surrounding tissue and, depending on its histologic subtype, spread to the lungs, bone or retroperitoneum.
In the World Health Organization (WHO) classification, liposarcoma is not a single disease but a family of cancers with distinct molecular genetics, microscopic features and outlook: well-differentiated liposarcoma (WDLPS), dedifferentiated liposarcoma (DDLPS), myxoid liposarcoma (MLS) and pleomorphic liposarcoma (PLS). Because it usually starts as a painless lump growing quietly in deep tissue, it is easily diagnosed late or shelled out with inadequate margins (R1/R2), leading to very high recurrence rates.
At Haute-Derma, we manage liposarcoma to international oncology standards: molecular characterization with FISH and immunohistochemistry (MDM2/CDK4/FUS-DDIT3), mapping of tumor extent with 3.0T MRI and PET-CT, and multidisciplinary team (MDT) review to plan curative wide resection (R0) that preserves as much function as possible.
Clinical and Pathological Classification
Causes and Molecular Genetics by Histologic Subtype
Liposarcoma falls into four main groups based on the driving genetic change:
- Well-differentiated liposarcoma (WDLPS):
- Carries amplification of the 12q13–15 region, leading to overexpression of MDM2 (which inhibits the tumor suppressor p53) and CDK4.
- Biologically identical to atypical lipomatous tumor (ALT). It does not metastasize unless it transforms into the dedifferentiated form (DDLPS).
- Dedifferentiated liposarcoma (DDLPS):
- Develops when WDLPS progresses to a high-grade tumor. In addition to MDM2/CDK4 amplification, DDLPS acquires other complex genetic changes (such as 1q21 or 6q23 amplification).
- High potential for distant spread (15–30%) and a very high rate of local recurrence.
- Myxoid liposarcoma (MLS):
- Defined by the specific translocation t(12;16)(q13;p11), which creates the FUS-DDIT3 fusion gene (about 95% of cases), or t(12;22)(q13;q12), which creates EWSR1-DDIT3.
- Accounts for about 30% of liposarcomas and tends to affect younger adults (30–50 years). It has a characteristic tendency to spread to soft tissue and bone sites outside the lungs (pelvis, spine, retroperitoneum).
- Pleomorphic liposarcoma (PLS):
- The rarest (<5%) but most dangerous subtype. It has a highly complex karyotype and often carries loss-of-function mutations in TP53 and RB1.
- Progresses very rapidly, with distant metastasis in 30–50% of cases (mainly to the lungs).
Pathology and Biomarkers (IHC and FISH) by Subtype
| Subtype | Immunohistochemistry (IHC) and Genetics (FISH) | Key Microscopic Features |
|---|---|---|
| Well-differentiated liposarcoma (WDLPS) | MDM2 (+); CDK4 (+); p16 (+); MDM2 gene amplification (+) | Fat cells of varying size; atypical hyperchromatic stromal cells within fibrous septa; scattered lipoblasts. |
| Dedifferentiated liposarcoma (DDLPS) | MDM2 (+); CDK4 (+); very high Ki-67 proliferation index (>30%) | WDLPS areas abruptly adjoining high-grade, non-fatty sarcoma (fibrosarcoma-like or pleomorphic). |
| Myxoid liposarcoma (MLS) | FUS-DDIT3 (+) by FISH; S100 (+/−); MDM2 (−) | Delicate branching "chicken-wire" capillary network; mucin-rich myxoid stroma; signet-ring lipoblasts. |
| Pleomorphic liposarcoma (PLS) | Extremely high Ki-67; patchy S100 (+); MDM2 usually (−) | Bizarre multinucleated pleomorphic lipoblasts; extensive necrosis; numerous atypical mitoses. |
Our Approach to Liposarcoma Care
Haute-Derma follows a multidisciplinary liposarcoma strategy based on the NCCN (National Comprehensive Cancer Network) sarcoma guidelines:
- Molecular confirmation with FISH and IHC: FISH detects MDM2 amplification and the FUS-DDIT3 translocation, allowing the subtype to be classified accurately from the core needle biopsy.
- Curative en bloc wide resection (R0): The surgeon removes the entire tumor with a cuff of surrounding healthy tissue (including the natural muscle fascia) without rupturing the tumor capsule, so cancer cells are not spilled into the surgical field.
- Preserving function with microsurgical reconstruction: Careful dissection of nerves and vessels combined with free muscle flap transfer repairs deep tissue defects so patients keep limb mobility after surgery.
- Multidisciplinary team (MDT) review: Decides on pre- or postoperative radiotherapy or systemic chemotherapy based on histologic subtype and grade.
How We Diagnose Liposarcoma at Haute-Derma
- Clinical exam and history: We assess soft tissue masses in the thigh, buttock, shoulder, abdomen or retroperitoneum. Sarcomas are typically firm, fixed, large (>5 cm) and deep to the muscle fascia.
- Multimodal imaging (3.0T MRI and PET-CT):
- Whole-body 3.0T MRI: Precisely defines the tumor margins and any invasion of fascia, blood vessels and nerve bundles.
- PET-CT (18F-FDG): Assesses metabolic activity (helping distinguish WDLPS from DDLPS) and screens for spread to the lungs, bone or abdomen.
- Ultrasound- or CT-guided core needle biopsy: A core needle biopsy (not an exploratory excision) is essential to obtain tissue for H&E staining, an immunohistochemistry panel and molecular FISH testing.
Specialized Treatment Options at Haute-Derma
- Curative wide resection (R0 resection, the cornerstone of treatment):
- Indication: The gold standard for all localized liposarcomas.
- Technique: A long incision gives wide exposure, and the tumor is removed in one piece with a safe margin of healthy tissue (>1–2 cm). When the tumor involves the retroperitoneum, the surgeon may also remove the surrounding perirenal fat or affected mesentery to achieve an R0 margin.
- Neoadjuvant / adjuvant radiotherapy:
- Preoperative (neoadjuvant) radiotherapy: Often used for myxoid liposarcoma (MLS), which is highly radiosensitive. Radiation shrinks the tumor and turns the myxoid stroma into fibrous tissue, making R0 surgery easier while sparing vessels and nerves.
- Postoperative (adjuvant) radiotherapy: Used for high-grade sarcomas (DDLPS, PLS) or when surgical margins are close (R1).
- Systemic chemotherapy and targeted therapy: Anthracycline-based regimens (doxorubicin) plus ifosfamide are used for MLS or PLS with a high risk of metastasis.
